Hims & Hers Health (NYSE:HIMS) stock fell 4.1% in after-hours trading on Thursday following a Bloomberg report that revealed ...

Telehealth and wellness platform Hims & Hers Health ($HIMS) recently disappointed investors with its mixed second-quarter ...

Through a trust, Dudum sold about $33.4 million worth of his company's stock on Thursday, according to a filing with the Securities and Exchange Commission put out after Monday's closing bell. The CEO ...

Current health news covers Novo Nordisk's ongoing lawsuits over Wegovy copies, influencer Michelle Miller's push for GMOs, IO Biotech's narrowly missed cancer vaccine goal, and China's ban on Spanish ...

In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

Novo Nordisk's legal actions against U.S. pharmacies over compounded copies of its drug Wegovy exclude Hims & Hers, a ...

Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending ...

Hims & Hers has been an incredible stock to own over the last few years, making shareholders rich. It has $2 billion in ...

SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

Novo Nordisk’s head of U.S. marketing, Ulrich Otte, is no longer in the role and is exploring other internal opportunities at the company outside of the U.S.